19 Aug
AA amyloidosis is a systemic disease caused by persistent inflammation and prolonged serum amyloid A production. It most often affects the kidneys, leading to proteinuria, nephrotic syndrome, and progressive kidney dysfunction. This article explains the causes, clinical features, diagnosis, amyloid typing, and treatment of AA amyloidosis.
READ MORE18 Aug
Echocardiography is central to recognizing cardiac amyloidosis. Explore the key echo red flags, including increased ventricular wall thickness, restrictive filling, reduced tissue Doppler velocities, impaired global longitudinal strain, and relative apical sparing.
READ MORE16 Aug
Cardiac amyloidosis in Africa remains under-recognized and under-researched. This article explores diagnostic barriers, genetic relevance, treatment access, workforce gaps, research priorities and opportunities to improve care across the continent.
READ MORE16 Aug
AL amyloidosis is caused by abnormal immunoglobulin light chains produced by a clonal plasma-cell disorder. Learn about key symptoms, cardiac and renal red flags, diagnostic testing, biopsy, amyloid typing and treatment.
READ MORE15 Aug
Cardiac amyloidosis treatment depends on the amyloid type. This guide explains current ATTR and AL therapies, including TTR stabilizers, TTR silencers, plasma-cell-directed treatment, diuretics, anticoagulation and multidisciplinary heart failure care.
READ MORE14 Aug
Cardiac amyloidosis diagnosis requires a structured approach. Learn how ECG, echocardiography, CMR, monoclonal protein testing, bone scintigraphy, biopsy and genetic testing are used to distinguish ATTR from AL amyloidosis.
READ MORE
We advance cardiac amyloidosis care across Africa through collaboration, training, and research. Join us to change the future of heart health and empower local clinicians with knowledge and tools.